Director of Clinical Service Provider Contracting Early Stage
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Director of Clinical Service Provider Contracting, Early Stage, will lead Service Provider sourcing, requests for information/proposal (RFIs/RFPs), contracting, and governance for assigned early-stage clinical programs.
This role will partner with Clinical Operations and study teams to define service requirements and establish agreements that support first-in-human, dose-escalation, and dose-expansion studies. The Director will manage contracting priorities, negotiate commercial terms,
